MADRID, April 16 Spain's Almirall and
Forest Laboratories said results of a first phase III
clinical trial for Almirall's Genuair inhaler were positive and
they would seek regulatory approval to sell the drug if further
results proved positive.
Results of a second phase III trial for the inhaler, which
delivers fixed dose combinations of aclidinium bromide and
formoterol fumarate to treat chronic obstructive pulmonary
disease (COPD), are expected in the coming weeks.
"In addition to the improved efficacy shown in this study,
the safety profile was comparable to placebo," Bertil Lindmark,
Almirall's Chief Scientific Officer, said on Tuesday.
If the next round of results are also positive, the
companies will file new drug applications to medical authorities
in the United States and Europe, Almirall said.
Almirall's share price has risen 70 percent over the past
year to close at 10.43 euros ($13.65) on Monday.